SCHEMBL714551

SCHEMBL714551

Cc1ccc(NC(=O)Nc2ccccc2Cl)cc1Nc1nc(-c2cccnc2)cs1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.65
KMT2A Q03164 7/20 0.65
RAB9A P51151 5/20 0.65
NPC1 O15118 4/20 0.65
ALDH1A1 P00352 2/20 0.65
NFKB1 P19838 1/20 0.65
NFKB2 Q00653 1/20 0.65
RELA Q04206 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
POLB P06746 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
GAA P10253 1/20 0.62
ABL1 P00519 7/20 0.59
BCR P11274 6/20 0.59
PDGFRB P09619 2/20 0.59
HDAC3 O15379 1/20 0.59
KDR P35968 1/20 0.59
HDAC4 P56524 1/20 0.59
HDAC1 Q13547 1/20 0.59
HDAC7 Q8WUI4 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5579274 0.90 GAA (0.67) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL716201 0.89 RAB9A (0.62) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL719497 0.89 RAB9A (0.62) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL717044 0.88 GAA (0.74) MEN1KMT2ARAB9ANPC1POLB
SCHEMBL14319701 0.86 GAA (0.65) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL717030 0.86 GAA (0.65) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL715934 0.86 GAA (0.65) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL14286286 0.85 MEN1 (0.64) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL715898 0.85 GAA (0.63) MEN1KMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL716370 0.85 GAA (0.63) MEN1KMT2ARAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100491374-C 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-KIT inhibitors AB SCIENCE (FR) 2009-05-27 CN claimed
US-20080255141-A1 Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders AB SCIENCE 2008-10-16 US claimed
US-7423055-B2 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. AB SCIENCE (FR) 2008-09-09 US claimed
EP-1525200-B1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2007-10-10 EP claimed
US-20070032521-A1 Use of c-kit inhibitors for treating type II diabetes AB SCIENCE 2007-02-08 US claimed
US-20050239852-A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2005-10-27 US claimed
CN-1684959-A 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-KIT inhibitors AB SCIENCE (FR) 2005-10-19 CN claimed
US-20040110810-A1 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. AB SCIENCE 2004-06-10 US claimed
US-8993573-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2015-03-31 US disclosed
US-8993573-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2015-03-31 US disclosed
US-8835435-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2014-09-16 US disclosed
US-8835435-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2014-09-16 US disclosed
US-20140088108-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS AB SCIENCE (FR) 2014-03-27 US disclosed
US-20140088108-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS AB SCIENCE (FR) 2014-03-27 US disclosed
CN-1684959-A 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-KIT inhibitors AB SCIENCE (FR) 2005-10-19 CN disclosed
EP-1525200-A1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB Science (FR) 2005-04-27 EP disclosed
WO-2005016323-A2 USE OF C-KIT INHIBITORS FOR TREATING TYPE II DIABETES AB SCIENCE (FR) 2005-02-24 WO disclosed
WO-2004096225-A2 USE OF TYROSINE KINASE INHIBITORS FOR TREATING CEREBRAL ISCHEMIA AB SCIENCE (FR) 2004-11-11 WO disclosed
US-20040110810-A1 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. AB SCIENCE 2004-06-10 US disclosed
WO-2004014903-A1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110810-A1 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. KIT, MAP3K2, CMA1 MEN1 2693/4885KMT2A 254/4885RAB9A 2337/4885
US-20070032521-A1 Use of c-kit inhibitors for treating type II diabetes KIT, CPA3, CMA1 MEN1 1706/4885KMT2A 359/4885RAB9A 1942/4885
US-20140088108-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS KIT, CHUK, CKS1B MEN1 3413/4885KMT2A 267/4885RAB9A 1773/4885
US-20050239852-A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors KIT, CHUK, MAP3K2 MEN1 3405/4885KMT2A 361/4885RAB9A 1962/4885
US-20080255141-A1 Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders KIT, MAP3K1, MAP3K6 MEN1 3551/4885KMT2A 974/4885RAB9A 3051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.